Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis-Reference-Cited by-同舟云学术

Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis

Published:2022 Issue:23 Volume:14 Page:2293-2303
ISSN:1759-9660
Container-title:Analytical Methods
language:en
Short-container-title:Anal. Methods

Author:

Li Zhuo¹²^ORCID,Sun Ning¹^ORCID,Zhang Qing³,Ma Hong-hao⁴,Wang Dong⁴,Zhao Yun-ze⁴,Yang Chang-qing²,Zhang Rui⁴^ORCID,Zhao Li-bo¹^ORCID

Affiliation:

1. Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 100045, China

2. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China

3. Hematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 100045, China

4. Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 100045, China

Abstract

A convenient, sensitive, and reliable LC-MS/MS method for the monitoring of ruxolitinib was developed, validated and applied to the clinical pharmacokinetic study of ruxolitinib in Chinese pediatric patients with hemophagocytic lymphohistiocytosis.

Funder

Ministry of Science and Technology of the People's Republic of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Engineering,General Chemical Engineering,Analytical Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/AY/D2AY00533F

Reference26 articles.

1. Ruxolitinib for the treatment of graft-versus-host disease

2. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis

3. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice

4. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

5. Ruxolitinib

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determination in plasma;Cancer Chemotherapy and Pharmacology;2024-09-11

2. The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells;Frontiers in Immunology;2024-08-12

3. IL-6 Blockade in Cytokine Storm Syndromes;Advances in Experimental Medicine and Biology;2024

4. Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions;Cancer Chemotherapy and Pharmacology;2022-12-13